MoonLake Immunotherapeutics (MLTX) Non-Current Assets (2020 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Non-Current Assets of $3.7 million for Q1 2026, down 25.31% year-over-year from $5.0 million in Q1 2025, and up 36.29% quarter-over-quarter from $2.7 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Non-Current Assets (2020 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $3.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 25.31% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (down 25.31% YoY), while the FY2025 annual figure was $2.7 million, down 24.84% from the prior year.
- Non-Current Assets for Q1 2026 stood at $3.7 million, up from $2.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $115.1 million in Q1 2022, with the low at $52679.0 in Q3 2022.
- The 5-year median for Non-Current Assets is $3.6 million (2024), against an average of $10.3 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets plunged 99.95% in 2022, then surged 3627.1% in 2023.
- MoonLake Immunotherapeutics' Non-Current Assets stood at $331969.0 in 2022, then soared by 3627.1% to $12.4 million in 2023, then tumbled by 70.55% to $3.6 million in 2024, then dropped by 24.84% to $2.7 million in 2025, then jumped by 36.29% to $3.7 million in 2026.
- Business Quant data shows MLTX's Non-Current Assets at $3.7 million in Q1 2026, $2.7 million in Q4 2025, and $3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 3.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.91 Mn |
| Mar 31, 2026 | 3.73 Mn |
| Dec 31, 2025 | 2.74 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Jun 30, 2025 | 4.62 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Sep 30, 2024 | 5.90 Mn |
| Jun 30, 2024 | 8.00 Mn |
| Mar 31, 2024 | 10.53 Mn |
| Dec 31, 2023 | 12.37 Mn |
| Sep 30, 2023 | 208,942.00 |
| Jun 30, 2023 | 254,048.00 |
| Mar 31, 2023 | 292,355.00 |
| Dec 31, 2022 | 331,969.00 |
| Sep 30, 2022 | 52,679.00 |
| Jun 30, 2022 | 55,971.00 |
| Mar 31, 2022 | 115.05 Mn |
| Dec 31, 2021 | 45,739.00 |
| Sep 30, 2021 | 115.04 Mn |